High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established. METHODS: We randomly assigned 4731 patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 to 4.9 mmol per liter), and had no known coronary heart disease to double-blind treatment with 80 mg of atorvastatin per day or placebo. The primary end point was a first nonfatal or fatal stroke. RESULTS: The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9 mmol per liter) among patients receiving atorvastatin and 129 mg per deciliter (3.3 mmol per liter) among patients receiving placebo. During a median follow-up of 4.9 years, 265 patients (11.2 percent) receiving atorvastatin and 311 patients (13.1 percent) receiving placebo had a fatal or nonfatal stroke (5-year absolute reduction in risk, 2.2 percent; adjusted hazard ratio, 0.84; 95 percent confidence interval, 0.71 to 0.99; P=0.03; unadjusted P=0.05). The atorvastatin group had 218 ischemic strokes and 55 hemorrhagic strokes, whereas the placebo group had 274 ischemic strokes and 33 hemorrhagic strokes. The five-year absolute reduction in the risk of major cardiovascular events was 3.5 percent (hazard ratio, 0.80; 95 percent confidence interval, 0.69 to 0.92; P=0.002). The overall mortality rate was similar, with 216 deaths in the atorvastatin group and 211 deaths in the placebo group (P=0.98), as were the rates of serious adverse events. Elevated liver enzyme values were more common in patients taking atorvastatin. CONCLUSIONS: In patients with recent stroke or TIA and without known coronary heart disease, 80 mg of atorvastatin per day reduced the overall incidence of strokes and of cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke. (ClinicalTrials.gov number, NCT00147602 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the recently published Lipitor's Effect in Alzheimer's Dementia (LEADe) trial, which included 640 randomized patients with mild Alzheimer disease, intensive lipid lowering by the addition of atorvastatin (80 mg) to donepezil did not improve cognitive function over a 72-week period.464”
In the citing paper
“Data from RCTs and meta-analyses indicate that routine early use of high-intensity statin therapy is associated with rapid and sustained clinical benefits [438-442].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [438]
In the citing paper
“Following stroke or TIA, 34 patients are at risk not only of recurrent cerebrovascular events but also of other major CV events including MI.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [34]
In the citing paper
“Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12%), MI and vascular death.422,428”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [428]
In the citing paper
“Many reports have also indicated that there is no clear relationship between the TG level and cerebrovascular disease856, 862, 863).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [862]
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis
Rankin, J. (1957) · Scottish Medical Journal · doi:10.1177/003693305700200504 · Cited by 2,506
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Iso, H., Jacobs, D. R., Wentworth, D., Neaton, J. D., Cohen, J. D., & for the MRFIT Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201405 · Cited by 1,133
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
Research works printed but not linked: 1
- Waters DD, 2005, Circulation, 112, 2020
Cited by
Items 601–700 of 1,005
Pathak, N. N., Balaganur, V., Lingaraju, M. C., More, A. S., Kant, V., Kumar, D., Kumar, D., & Tandan, S. K. (2013) · Inflammation · doi:10.1007/s10753-013-9688-x · Cited by 50
Newman, C. B., Szarek, M. J., Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., DeMicco, D. A., Auster, S. B., & Fuller, J. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.029 · Cited by 49
Chung, J., Hwang, J., Lee, M. J., Cha, J., & Bang, O. Y. (2016) · Stroke · doi:10.1161/strokeaha.116.013495 · Cited by 51
Persistent User Bias in Case-Crossover Studies in Pharmacoepidemiology
Hallas, J., Pottegård, A., Wang, S. V., Schneeweiß, S., & Gagne, J. J. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kww079 · Cited by 48
Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines
Mohler, E. R., & Giri, J. S. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802274379 · Cited by 53
Guidelines for Acute Ischemic Stroke Treatment
Qiu, S., & Xu, Y. (2020) · Neuroscience Bulletin · doi:10.1007/s12264-020-00534-2 · Cited by 48
Wu, Z., Huang, Z., Lichtenstein, A. H., Liu, Y., Chen, S., Jin, Y., Na, M., Bao, L., Wu, S., & Gao, X. (2021) · BMC Medicine · doi:10.1186/s12916-021-02014-4 · Cited by 50
Atorvastatin in stroke: a review of SPARCL and subgroup analysis
Zivin, J. A., & Stemer (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6795 · Cited by 53
Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells
Tapia-Pérez, J. H., Kirches, E., Mawrin, C., Firsching, R. P., & Schneider, T. L. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1535-2 · Cited by 47
Yeramaneni, S., Kleindorfer, D., Sucharew, H. J., Alwell, K., Moomaw, C. J., Flaherty, M. L., Woo, D., Adeoye, O. M., Ferioli, S., Rosa, F. D. L. R. L., et al. (2016) · International Journal of Stroke · doi:10.1177/1747493016670175 · Cited by 47
Nannucci, S., Rinnoci, V., Pracucci, G., MacKinnon, A. D., Pescini, F., Adib‐Samii, P., Bianchi, S., Dotti, M. T., Federico, A., Inzitari, D., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190878 · Cited by 48
Updates on Prevention of Hemorrhagic and Lacunar Strokes
Tsai, H.-H., Kim, J., Jouvent, E., & Gurol, M. (2018) · Journal of Stroke · doi:10.5853/jos.2018.00787 · Cited by 44
Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage
Kearns, K. N., Ironside, N. T., Park, M. S., Worrall, B. B., Southerland, A. M., Chen, C., & Ding, D. (2021) · Neurocritical Care · doi:10.1007/s12028-021-01311-3 · Cited by 46
Platelets, Arterial Thrombosis and Cerebral Ischemia
Badimón, L., & Vilahur, G. (2007) · Cerebrovascular Diseases · doi:10.1159/000107377 · Cited by 46
Yang, Q., Sun, D., Pei, C., Zeng, Y. H., Wang, Z., Li, Z., Hao, Y., Song, X., Li, Y., Liu, G., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab418 · Cited by 45
Self-citationSingapore Ministry of Health Clinical Practice Guidelines on Stroke and Transient Ischemic Attacks
Venketasubramanian, N., Pwee, K. H., & Chen, C. (2011) · International Journal of Stroke · doi:10.1111/j.1747-4949.2011.00602.x · Cited by 44
Therapeutic Interventions and Success in Risk Factor Control for Secondary Prevention of Stroke
Álvarez‐Sabín, J., Quintana, M., Hernández-Presa, M. Á., Alvarez, C., Chaves, J., & Ribó, M. (2009) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2009.01.014 · Cited by 46
Hospital costs of ischemic stroke and TIA in the Netherlands
Buisman, L. R., Tan, S. S., Nederkoorn, P. J., Koudstaal, P. J., & Redekop, K. (2015) · Neurology · doi:10.1212/wnl.0000000000001635 · Cited by 46
A Neuromuscular Approach to Statin-Related Myotoxicity
Baker, S. K., & Samjoo, I. A. (2008) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100007514 · Cited by 66
Primary and Secondary Prevention of Ischemic Stroke
Paciaroni, M., & Bogousslavsky, J. (2010) · European Neurology · doi:10.1159/000285183 · Cited by 51
Effect and Safety of Rosuvastatin in Acute Ischemic Stroke
Heo, J. H., Song, D., Nam, H. S., Kim, E. Y., Kim, Y. D., Lee, K., Lee, K., Yoo, J., Kim, Y. N., Lee, B. C., et al. (2016) · Journal of Stroke · doi:10.5853/jos.2015.01578 · Cited by 48
Chen, Q., Shi, X., Tan, Q., Feng, Z., Wang, Y., Yuan, Q., Tao, Y., Zhang, J., Tan, L., Zhu, G., et al. (2017) · Translational Stroke Research · doi:10.1007/s12975-017-0521-y · Cited by 49
Atherogenic Dyslipidemia and Residual Vascular Risk After Stroke or Transient Ischemic Attack
Hoshino, T., Ishizuka, K., Toi, S., Mizuno, T., Nishimura, A., Takahashi, S., Wako, S., & Kitagawa, K. (2021) · Stroke · doi:10.1161/strokeaha.121.034593 · Cited by 49
Bétrisey, S., Haller, M. L., Efthimiou, O., Speierer, A., Giovane, C. D., Moutzouri, E., Blum, M. R., Aujesky, D., Rodondi, N., & Gencer, B. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030714 · Cited by 49
Reith, C. A., Blackwell, L. S., Emberson, J., Preiss, D., Spata, E., Davies, K., Halls, H. J., Harper, C., Holland, L., Wilson, K., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)01578-8 · Cited by 68
Şeker, F. B., Kılıç, Ü., Çağlayan, B., Ethemoglu, M. S., Çağlayan, A. B., Gürcan, N. E., Demirci, S., Doğan, A., Öztezcan, S., Sahin, F., et al. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.014 · Cited by 44
“3-Hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors (also known as statins) are widely prescribed for the treatment of hypercholesterolemia, prevention of secondary stroke and ischemic heart disease (Amarenco et al., 2006).”
BackgroundContinued statin therapy could improve the outcome after spontaneous intracerebral hemorrhage
Tapia-Pérez, J. H., Rupa, R., Zilke, R., Gehring, S., Voellger, B., & Schneider, T. (2012) · Neurosurgical Review · doi:10.1007/s10143-012-0431-0 · Cited by 47
Treatment of Atherosclerotic Intracranial Arterial Stenosis
Turan, T. N., Derdeyn, C. P., Fiorella, D., & Chimowitz, M. I. (2009) · Stroke · doi:10.1161/strokeaha.108.537589 · Cited by 43
Restrepo, L., Bang, O. Y., Ovbiagele, B. I., Ali, L. K., Kim, D., Liebeskind, D. S., Starkman, S., Viñuela, F., Duckwiler, G., Jahan, R., et al. (2009) · Cerebrovascular Diseases · doi:10.1159/000235625 · Cited by 49
Recent Nationwide Trends in Discharge Statin Treatment of Hospitalized Patients With Stroke
Ovbiagele, B. I., Schwamm, L. H., Smith, E. E., Hernandez, A. F., Olson, D. M., Pan, W., Fonarow, G. C., & Saver, J. L. (2010) · Stroke · doi:10.1161/strokeaha.109.573618 · Cited by 44
Discharge Is a Critical Time to Influence 10-Year Use of Secondary Prevention Therapies for Stroke
Thrift, A. G., Kim, J., Douzmanian, V., Gall, S., Arabshahi, S., Loh, M., & Evans, R. G. (2013) · Stroke · doi:10.1161/strokeaha.113.003368 · Cited by 44
MR Imaging of the Arterial Vessel Wall: Molecular Imaging from Bench to Bedside
Makowski, M. R., & Botnar, R. M. (2013) · Radiology · doi:10.1148/radiol.13102336 · Cited by 50
Addison, D., Lawler, P. R., Emami, H., Janjua, S., Staziaki, P. V., Hallett, T. R., Hennessy, O., Lee, H., Szilveszter, B., Lu, M. T., et al. (2018) · Journal of Stroke · doi:10.5853/jos.2017.01802 · Cited by 45
PCSK9 inhibitors and cardiovascular outcomes
Steffens, D., Bramlage, P., Scheeff, C., Kasner, M., Hassanein, A., Friebel, J., & Rauch-Kröhnert, U. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1677604 · Cited by 43
Early Atorvastatin Reduces Hemorrhage after Acute Cerebral Ischemia in Diabetic Rats
Elewa, H. F., Kozak, A., El‐Remessy, A. B., Frye, R. F., Johnson, M. H., Ergul, A., & Fagan, S. C. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146951 · Cited by 49
Prediction of long-term functional outcome in patients with acute ischemic non-embolic stroke
Protopsaltis, J., Kokkoris, S., Korantzopoulos, P. G., Milionis, H. J., Karzi, E., Anastasopoulou, A., Filioti, K., Antonopoulos, S., Melidonis, A. J., & Giannoulis, G. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.05.042 · Cited by 44
Secondary Prevention of Atherothrombotic Events After Ischemic Stroke
Adams, H. P. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.1.43 · Cited by 50
Cerebrovascular Events in Renal Transplant Recipients
Abedini, S., Holme, I., Fellström, B., Jardine, A. G., Cole, E., Maes, B., & Holdaas, H. (2009) · Transplantation · doi:10.1097/tp.0b013e31818bfce8 · Cited by 44
The association of statin therapy and cancer: a meta-analysis
Chen, Z., Wu, P., Wang, J., Chen, P., Fang, Z., & Luo, F. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01955-4 · Cited by 48
Impact of inhaled nitric oxide on white matter damage in growth-restricted neonatal rats
Pham, H., Duy, A. P., Pansiot, J., Bollen, B., Gallego, J., Charriaut‐Marlangue, C., & Baud, O. (2015) · Pediatric Research · doi:10.1038/pr.2015.4 · Cited by 45
Role of Statin in Atrial Fibrillation-Related Stroke: An Angiographic Study for Collateral Flow
Lee, M. J., Bang, O. Y., Kim, S. J., Kim, G. M., Chung, C. S., Lee, K. H., Ovbiagele, B. I., Liebeskind, D. S., Saver, J. L., & Collaborators, F. T. U.-S. S. (2014) · Cerebrovascular Diseases · doi:10.1159/000356114 · Cited by 44
Lavallée, P. C., Labreuche, J., Góngora‐Rivera, F., Jaramillo, A., Brenner, D., Klein, I. F., Touboul, P., Vicaut, É., & Amarenco, P. (2009) · Stroke · doi:10.1161/strokeaha.108.540088 · Cited by 47
Statins Improve Survival in Patients With Cardioembolic Stroke
Choi, J., Seo, W., Kang, S. H., Jung, J., Cho, K., Yu, S., & Oh, K. (2014) · Stroke · doi:10.1161/strokeaha.114.005518 · Cited by 43
Does Simvastatin Cause More Myotoxicity Compared with Other Statins?
Backes, J. M., Howard, P. A., Ruisinger, J. F., & Moriarty, P. M. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m410 · Cited by 46
Zhou, Z.-Y., Huang, B., Li, S., Huang, X.-H., Tang, J., Kwan, Y. W., Hoi, M. P. M., & Lee, S. M. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.04.037 · Cited by 42
“For example, in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, high-dose atorvastatin (Ator) (80mg per day) shown a small significant increase in the incidence of hemorrhagic stroke in patients with recent stroke or transient ischemic attack (TIA) (Amarenco et al., 2006).”
InfluentialRibe, A. R., Vestergaard, C. H., Vestergaard, M., Fenger‐Grøn, M., Pedersen, H. S., Lietzen, L. W., & Brynningsen, P. K. (2019) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.02.007 · Cited by 43
“However, post-hoc analyses of data from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial suggested that statinsmay increase the risk of intracerebral haemorrhage (ICH) in individuals with previous stroke [1,4], but these results could not be confirmed by two meta-analyses [5,6] or a l…”
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Schmidt, A. F., Holmes, M. V., Preiss, D., Swerdlow, D. I., Denaxas, S., Fatemifar, G., Faraway, R., Finan, C., Lumbers, R. T., Henry, A., et al. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1187-z · Cited by 42
Effect of Statin Therapy on Outcomes of Patients With Acute Ischemic Stroke and Atrial Fibrillation
Choi, K., Seo, W., Park, M., Kim, J., Chung, J., Bang, O. Y., Kim, G., Song, T., Kim, B. J., Heo, S. H., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013941 · Cited by 45
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories
Szarek, M. J., Amarenco, P., Callahan, A., DeMicco, D. A., Fayyad, R. S., Goldstein, L. B., Laskey, R. E., Sillesen, H. H., & Welch, K. M. A. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.015 · Cited by 47
Kukharchuk, V. V., Владиславович, Е. М., Викторович, С. И., Arabidze, G. G., Балахонова, Т. В., Gurevich, V. S., Zelveyan, P. A., Murataliev, T. M., Myrzakhmetova, G., Александровна, С. О., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-2-6-29 · Cited by 51
Prasad, K., Kaul, S., Padma, M., Gorthi, S. P., Khurana, D., & Bakshi, A. (2011) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.83084 · Cited by 53
Burger, P. M., Dorresteijn, J. A. N., Koudstaal, S., Holtrop, J., Kastelein, J. J. P., Jukema, J. W., Ridker, P. M., Mosterd, A., & Visseren, F. L. J. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118540 · Cited by 62
Statin tolerability: In defence of placebo-controlled trials
Tobert, J. A., & Newman, C. B. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487315602861 · Cited by 42
Secondary stroke prevention in the elderly: New evidence in hypertension and hyperlipidemia
Castilla‐Guerra, L., Fernández‐Moreno, M. D. C., & Suero, J. Á. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.06.005 · Cited by 48
Bousser, M. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0178-6 · Cited by 47
Uchiyama, S., Ikeda, Y., Urano, Y., Horie, Y., & Yamaguchi, T. (2011) · Cerebrovascular Diseases · doi:10.1159/000327035 · Cited by 42
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 61
Steen, D. L., Khan, I., Ansell, D., Sanchez, R. J., & Ray, K. K. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013255 · Cited by 49
Association of statin use with spontaneous intracerebral hemorrhage: A cohort study
Saliba, W., Rennert, H. S., Barnett‐Griness, O., Gronich, N., Molad, J., Rennert, G., & Auriel, E. (2018) · Neurology · doi:10.1212/wnl.0000000000005907 · Cited by 48
Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization
Hussain, M. A., Saposnik, G., Raju, S., Salata, K., Mamdani, M., Tu, J. V., Bhatt, D. L., Verma, S., & Al-Omran, M. A. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009745 · Cited by 44
Treatment Approaches to Lacunar Stroke
Das, A. S., Regenhardt, R. W., Feske, S. K., & Gurol, M. E. (2019) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2019.05.004 · Cited by 46
Statin treatment and cerebral microbleeds: A systematic review and meta-analysis
Katsanos, A. H., Lioutas, V., Charidimou, A., Catanese, L., Ng, K. K. H., Perera, K. S., Boasquevisque, D. D. S., Falcone, G. J., Sheth, K. N., Romero, J. R., et al. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.117224 · Cited by 42
Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients
Davis, J. W., & Weller, S. C. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043714 · Cited by 48
Zweifler, R. M., McClure, L. A., Howard, V. J., Cushman, M., Hovater, M. K., Safford, M. M., Howard, G., & Goff, D. C. (2011) · Neuroepidemiology · doi:10.1159/000328258 · Cited by 45
Neuroprotective Effects of Statins: Evidence from Preclinical and Clinical Studies
Fisher, M., & Moonis, M. (2012) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-012-0174-9 · Cited by 45
Beretta, S., Pastori, C., Sala, G., Piazza, F., Ferrarese, C., Cattalini, A., de Curtis, M., & Librizzi, L. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.003 · Cited by 45
ApoB100 and Atherosclerosis: What’s New in the 21st Century?
Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Evangelopoulos, A. A., Panagopoulos, F., Stratigou, T., Geladari, E. V., Karampela, Ι., & Dalamaga, Μ. (2024) · Metabolites · doi:10.3390/metabo14020123 · Cited by 55
Safety and Effect of Very Low Levels of Low-Density Lipoprotein Cholesterol on Cardiovascular Events
LaRosa, J. C., Pedersen, T. R., Somaratne, R. M., & Wasserman, S. M. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.052 · Cited by 49
Optimal combination secondary prevention drug treatment and stroke outcomes
Park, J., & Ovbiagele, B. I. (2014) · Neurology · doi:10.1212/wnl.0000000000001099 · Cited by 45
Yamada, K., Yoshimura, S., Kawasaki, M., Enomoto, Y., Asano, T., Minatoguchi, S., & Iwama, T. (2009) · Cerebrovascular Diseases · doi:10.1159/000235746 · Cited by 45
Prior use of statins and outcome in patients with intracerebral haemorrhage
Eichel, R., Khoury, S. T., Ben‐Hur, T., Keidar, M., Paniri, R., & Leker, R. R. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02747.x · Cited by 47
Charlton-Menys, V., Betteridge, D. J., Colhoun, H. M., Fuller, J., France, M. W., Hitman, G. A., Livingstone, S. J., Neil, H. A. W., Newman, C. B., Szarek, M. J., et al. (2008) · Diabetologia · doi:10.1007/s00125-008-1176-8 · Cited by 42
Zhang, J., Mu, X., Breker, D. A., Li, Y., Gao, Z., & Huang, Y. (2016) · International Journal of Neuroscience · doi:10.3109/00207454.2016.1146882 · Cited by 44
Utilization of Statins Beyond the Initial Period After Stroke and 1‐Year Risk of Recurrent Stroke
Lee, M., Saver, J. L., Wu, Y., Tang, S., Lee, J., Rao, N. M., Wang, H., Jeng, J., Lee, T., Chen, P., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005658 · Cited by 44
Adult Stem Cells in Vascular Remodeling
Wang, D., Li, L. K., Dai, T., Wang, A., & Li, S. (2017) · Theranostics · doi:10.7150/thno.19577 · Cited by 47
Guo, Y., Li, Y., Liu, X., Cui, Y., Zhao, Y., Sun, S., Jia, Q., Chai, Q., Gong, G. X., Zhang, H., et al. (2020) · BMC Geriatrics · doi:10.1186/s12877-020-01682-w · Cited by 45
Statins in Intracerebral Hemorrhage
Lauer, A., Greenberg, S. M., & Gurol, M. E. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0526-5 · Cited by 42
Additive Effects of Statin and Dipyridamole on Cerebral Blood Flow and Stroke Protection
Kim, H.-H., Sawada, N., Soydan, G., Lee, H.-S., Zhou, Z., Hwang, S., Waeber, C., Moskowitz, M. A., & Liao, J. K. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.24 · Cited by 41
Restenosis after carotid endarterectomy: significance of newly acquired risk factors
Fluri, F., Hatz, F., Voss, B., Lyrer, P. A., & Engelter, S. T. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02858.x · Cited by 41
Perspectives on low-density-lipoprotein cholesterol goal achievement
Catapano, A. L. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802631438 · Cited by 40
Chang, C., Chang, Y., Lee, Y., Liu, Y., Chuang, L., & Lin, J. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12657 · Cited by 40
PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Do, R. Q., Vogel, R. A., & Schwartz, G. G. (2013) · Current Cardiology Reports · doi:10.1007/s11886-012-0345-z · Cited by 43
Carotid atherosclerotic plaque stenosis: the stabilizing role of statins
Artom, N., Montecucco, F., Dallegri, F., & Pende, A. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12340 · Cited by 42
Goldfinger, J. Z., Kronish, I. M., Fei, K., Graciani, A., Rosenfeld, P., Lorig, K. R., & Horowitz, C. R. (2012) · Contemporary Clinical Trials · doi:10.1016/j.cct.2012.06.003 · Cited by 49
Bangalore, S., Fayyad, R. S., Hovingh, G. K., Laskey, R. E., Vogt, L., DeMicco, D. A., & Waters, D. D. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.03.046 · Cited by 43
Coronary Risk Stratification in Patients with Ischemic Stroke or Transient Ischemic Stroke Attack
Touzé, E., Varenne, O., Calvet, D., & Mas, J. (2007) · International Journal of Stroke · doi:10.1111/j.1747-4949.2007.00136.x · Cited by 43
Baldwin, K., Orr, S. C., Briand, M. E., Piazza, C., Veydt, A., & McCoy, S. L. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.5.493 · Cited by 45
Naci, H., Brugts, J. J., Fleurence, R., & Ades, A. E. (2013) · QJM · doi:10.1093/qjmed/hct041 · Cited by 43
Sawada, N., & Liao, J. K. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.70 · Cited by 41
Statins for acute ischemic stroke
Squizzato, A., Romualdi, E., Dentali, F., & Ageno, W. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007551.pub2 · Cited by 40
Medical Treatment of Intracranial Atherosclerosis: An Update
Kim, J. S., & Bang, O. Y. (2017) · Journal of Stroke · doi:10.5853/jos.2017.01830 · Cited by 40
Genetics of Spontaneous Intracerebral Hemorrhage
Falcone, G. J., & Woo, D. (2017) · Stroke · doi:10.1161/strokeaha.117.017072 · Cited by 43
Cardiovascular magnetic resonance in carotid atherosclerotic disease
Dong, L., Kerwin, W. S., Ferguson, M. S., Li, R., Wang, J., Chen, H., Cantón, G., Hatsukami, T. S., & Yuan, C. (2009) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-11-53 · Cited by 43
Pezzini, A., Grassi, M., Iacoviello, L., Zedde, M., Marcheselli, S., Silvestrelli, G., DeLodovici, M. L., Sessa, M., Zini, A., Paciaroni, M., et al. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312736 · Cited by 43
Zanchetti, A., Liu, L., Mancia, G., Parati, G., Grassi, G. M., Stramba‐Badiale, M., Silani, V., Bilo, G., Corrao, G., Zambon, A., et al. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000253 · Cited by 40
“Although the absolute increase in incidence of haemorrhagic stroke was small in SPARCL, the problem may be more important in the Far East, where haemorrhagic stroke is more frequent.”
BackgroundInfluentialPharmacologic Preconditioning: Translating the Promise
Gidday, J. M. (2010) · Translational Stroke Research · doi:10.1007/s12975-010-0011-y · Cited by 42
Johnston, S. C., Sidney, S., Hills, N. K., Grosvenor, D., Klingman, J. G., BERNSTEIN, A. L., & Levin, E. G. (2010) · Annals of Neurology · doi:10.1002/ana.22019 · Cited by 43
Shin, J., Park, J. B., Kim, K., Kim, J. H., Yang, D. H., Pyun, W. B., Kim, Y. G., Kim, G., & Chae, S. C. (2015) · Clinical Hypertension · doi:10.1186/s40885-014-0013-2 · Cited by 42
Prognostic significance of major lipids in patients with acute ischemic stroke
Τζιόμαλος, Κ., Giampatzis, V., Bouziana, S. D., Spanou, M., Kostaki, S., Papadopoulou, M., Angelopoulou, S.-M., Tsopozidi, M., Savopoulos, C. G., & Hatzitolios, A. I. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-016-9924-9 · Cited by 42
The effect of ABCA1gene polymorphisms on ischaemic stroke risk and relationship with lipid profile
Pasdar, A., Yadegarfar, G., Cumming, A. M., Whalley, L. J., Clair, D. S., & MacLeod, M. J. (2007) · BMC Medical Genetics · doi:10.1186/1471-2350-8-30 · Cited by 42
Metadata
- Authors
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Affiliations
- Université Paris Diderot (FR)
- Corresponding author
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-08-10
- Volume
- 355
- Issue
- 6
- Pages
- 549-559
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1546258268
- Cited by
- 2,887
- References
- 21
- Citations by year
- 2026: 86 · 2025: 96 · 2024: 119 · 2023: 112 · 2022: 135 · 2021: 134 · 2020: 139 · 2019: 140 · 2018: 129 · 2017: 132 · 2016: 139 · 2015: 125 · 2014: 142 · 2013: 160 · 2012: 149
- FWCI
- 200.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Eisai
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
- Keywords
- atorvastatin, high-intensity statin therapy, stroke, transient ischemic attack, secondary stroke prevention, LDL cholesterol lowering, hemorrhagic stroke, ischemic stroke, cardiovascular events, elevated liver enzymes, lipid-lowering therapy, mortality, serious adverse events
- MeSH terms
- Atorvastatin, Adult, Cardiovascular Diseases, Cerebral Hemorrhage, Cerebral Infarction, Ischemic Attack, Transient, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Pyrroles, Risk, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.